Key ideas from Brigham Buhler

• The FDA is working to reclassify peptides and remove black box warnings on testosterone therapy under Kennedy's administration
• Four out of five peptides being filled are through gray or black market solutions with no clinician oversight
• Muse stem cells can differentiate into any damaged cell type with 15-30% engraftment rates versus 3-5% for traditional MSCs
• Testosterone therapy fears stem from a 1930s study with only three patients, one of whom dropped out
• 60-80% of FDA-approved drugs will have major label changes or recalls according to FDA's own data
• Plasmapheresis can remove 70% of inflammatory markers and microplastics from blood in a single treatment
• Gene sequencing reveals predispositions like Gordon Ryan's rare tendon density gene (one in 10 million)
• The average American is on four or more prescription drugs in a system designed to monetize chronic disease